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Experimental Conversion of Liver to Pancreas
forward is to produce  cells in vitro for transplantation.Marko E. Horb,* Chia-Ning Shen, David Tosh,
and Jonathan M.W. Slack Although this may eventually become possible with islet
progenitor cells, adult stem cells, or embryonic stemCentre for Regenerative Medicine
Department of Biology and Biochemistry cells, this work is currently at an early stage. An alterna-
tive method, which involves reprogramming liver cellsUniversity of Bath
Bath BA2 7AY into pancreas cells, would overcome the problems, but
recent attempts to achieve this have also been unsuc-United Kingdom
cessful.
“Transdifferentiation” is the name used to describe
the conversion of one differentiated cell type to anotherSummary
[4–7]. It belongs to a wider class of cell type conversions
known as “metaplasias,” which also include switchesBackground: The liver and the pancreas arise from adja-
in fate between stem cells of different tissues [4, 5].cent regions of endoderm in embryonic development.
Transdifferentiation and metaplasia are important for aPdx1 is a key transcription factor that is essential for
number of reasons. Firstly, identification of the switchesthe development of the pancreas and is not expressed
involved may provide information on the molecular basisin the liver. The aim of this study was to determine
of normal developmental mechanisms. Secondly, somewhether a gene overexpression protocol based on Pdx1
metaplasias predispose to neoplasia, and so their pre-would be able to cause conversion of liver to pancreas.
vention has a direct health benefit. For example, in Bar-Results: We show that a modified form of Pdx1, car-
rett’s esophagus, the lower end of the esophagus isrying the VP16 transcriptional activation domain, can
converted to stomach or intestinal-type tissue, and thiscause conversion of liver to pancreas, both in vivo and
can be a precursor to oesophageal adenocarcinoma [8].in vitro. Transgenic Xenopus tadpoles carrying the con-
Thirdly, and of much current interest, understanding thestruct TTR-Xlhbox8-VP16:Elas-GFP were prepared.
rules for transdifferentiation between cell types will im-Xlhbox8 is the Xenopus homolog of Pdx1, the TTR (trans-
prove our ability to reprogram stem cells or differenti-thyretin) promoter directs expression to the liver, and
ated adult cells for the purposes of therapeutic trans-the GFP is under the control of an elastase promoter
plantation.and provides a real-time visible marker of pancreatic
An example of transdifferentiation that has been welldifferentiation. In the transgenic tadpoles, part or all
studied is the conversion of pancreas to liver [9]. Thisof the liver is converted to pancreas, containing both
has been described in both in vivo and in vitro experi-exocrine and endocrine cells, while liver differentiation
mental models. For example, copper deprivation in theproducts are lost from the regions converted to pan-
rat induces hepatocytes in the pancreas [10, 11]. Ourcreas. The timing of events is such that the liver is differ-
labs have recently produced an in vitro model for theentiating by the time Xlhbox8-VP16 is expressed, so we
transdifferentiation of pancreatic cells to hepatocytesconsider this a transdifferentiation event rather than a
based on culture with the glucocorticoid dexametha-reprogramming of embryonic development. Further-
sone [12]. The hepatocytes are formed directly frommore, this same construct will bring about transdifferen-
exocrine cells, and this switch can be activated by thetiation of human hepatocytes in culture, with formation
transcription factor C/EBP [12]. The reverse transdif-of both exocrine and endocrine cells.
ferentiation of liver to pancreas has been found to occurConclusions: We consider that the conversion of liver
in the livers of rats treated with polychlorinated biphe-to pancreas could be the basis of a new type of therapy
nyls [13], in fish liver tumors induced by chemical carcin-for insulin-dependent diabetes. Although expression of
ogens [14], and in the liver of a human patient withthe transgene is transient, once the ectopic pancreas
hepatic cirrhosis [15]. Endocrine tissue, however, wasis established, it persists thereafter.
not present in any of these examples.
The pancreas and liver arise from adjacent areas in
Introduction the anterior endoderm of the developing embryo [16].
It has been proposed that a common precursor cell
A total of 150 million people worldwide currently suffer exists and that signals from the cardiac mesoderm are
from diabetes, and that number is predicted to rise to responsible for specifying the two organs [17, 18]. In
300 million over the next 20 years [1]. A minority are this model, the default state of the ventral foregut endo-
type 1 diabetics who usually require insulin treatment derm is to become pancreas, but an FGF-like signal
for survival. The majority are type 2 diabetics, a propor- released from the cardiac mesoderm diverts the fate of
tion of who have some element of pancreatic pathology some cells into liver. These results suggest that the liver
and may also require insulin treatment [2]. Transplanta- and pancreas differ by a single developmental decision,
tion therapies for diabetes have been explored for many presumably affecting the expression of a relatively small
years, but islet cell transplants still involve serious prob- number of genes, and that experimental interconversion
lems of immune rejection and donor supply [3]. One way between the two tissues should therefore be possible.
Numerous transcription factors have been identified
that are known to play an important role in the specifica-*Correspondence: m.horb@bath.ac.uk
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tion of the different cell types within the pancreas [19– Initially, liver and pancreas development occur nor-
mally in transgenic tadpoles containing TTR-Xlhbox8-21]. Of these, the one that has the most likelihood of
encoding the difference between liver and pancreas is VP16, with Elas-GFP only being expressed in the dorsal
and ventral pancreatic buds (Figure 1D). From stage 45Pdx1. It is expressed early in the endoderm prior to
overt morphological development of the pancreas and (5 days), many individuals also show an anterior patch
of fluorescence in the position normally occupied by thehas been shown to play a fundamental role in pancreatic
development [22]. In Pdx1 knockout mice, pancreatic liver (Figures 1E–1I). In the method used, each trans-
genic tadpole represents a separate integration event,tissue is missing. Although initial specification does oc-
cur, no mature pancreas is formed [23, 24]. In humans, with differing gene copy numbers integrating into differ-
ent sites in the host genome; thus, some variation inthe lack of a functional Pdx1 protein also results in agen-
esis of the pancreas [25]. Several groups have overex- results is to be expected. The proportion of transgenic
individuals showing ectopic pancreas is 61%, and thesepressed Pdx1 in various sites but have not so far suc-
ceeded in producing ectopic pancreas [26–28]. We felt may be complete or partial transformations of liver to
pancreas, with the rest of the tadpole appearing normal.that the lack of success in these experiments might be
due to the lack of appropriate protein partners in the In all positive cases, the ectopic pancreatic tissue, visu-
alized by an ectopic patch of GFP fluorescence, istarget tissues and have therefore taken a different ap-
proach by using a modified form of Pdx1 for which pro- clearly distinguishable from the endogenous pancreas
(Figure 1G).tein partners are unlikely to be necessary.
Using a tissue-specific promoter, we have produced To determine unequivocally whether the ectopic Elas-
GFP expression represents true conversion of liver totransgenic Xenopus tadpoles that overexpress an acti-
vated form of the Xenopus homolog of Pdx1, Xlhbox8- pancreas, we examined the expression of several pan-
creatic differentiation products. Insulin and glucagonVP16, in the liver. This causes a conversion of liver to
pancreatic tissue, containing both exocrine and endo- are the principal hormones produced, respectively, by
- and-type endocrine cells. In normal tadpoles, insulincrine cell types. To confirm that this result is not limited
to Xenopus, or to larval stages of development, we have mRNA is detected in the dorsal pancreas prior to stage
47 (7 days) (Figure 2A) [37, 38]. In TTR-Xlhbox8-VP16also transfected Xlhbox8-VP16 into the human hepa-
toma cell line, HepG2. This is also converted into pancre- transgenic tadpoles, ectopic insulin is also detected in
the region of the liver (Figures 2B and 2C). Glucagonatic cells, which express either amylase or insulin. These
results show that overexpression of an activated form expression is normally found in small groups of cells in
the pancreas beginning at stage 45, as well as in theof Pdx1 can induce the formation of pancreas from liver,
in a process that we consider to be a transdifferentiation enteroendocrine cells of the stomach and small intestine
(Figure 2D) [37–39]. In TTR-Xlhbox8-VP16 transgenicevent. They demonstrate that it is possible to switch
one tissue to another by overexpression of a single tran- tadpoles, ectopic glucagon expression can also be seen
in the normal position of the liver (Figures 2E and 2F).scription factor and suggest a possible novel therapy
for diabetes based on the transdifferentiation of liver Amylase is a major product of the pancreatic exocrine
cells [40]. In TTR-Xlhbox8-VP16 transgenic tadpoles,cells.
amylase mRNA is expressed in the ectopic pancreatic
tissue in identical regions to the Elas-GFP expression
Results (Figures 2G–2I). In the example shown here, part of the
liver has become pancreas, but the portion marked L
Xlhbox8-VP16 Causes Conversion does not express either GFP or amylase and is presum-
of Liver to Pancreas ably unchanged. These results demonstrate that the
In order to produce a version of Pdx1 that would activate region expressing GFP in the transgenics is differenti-
target genes without the need for protein partners, the ated pancreas, containing both exocrine and endocrine
VP16 activation domain from Herpes simplex virus [29– tissues.
31] was fused to the C terminus of Xlhbox8, the Xenopus To begin to understand the mechanism of the process,
homolog of Pdx1 [32]. We then used a transgenic we have used RT-PCR to examine whether the endoge-
method [33] to express Xlhbox8-VP16 in the liver of nous Xlhbox8 is activated in the liver upon transient
Xenopus tadpoles. The Xlhbox8-VP16 is driven by the expression of Pdx1-VP16. As shown below, the mouse
murine transthyretin (TTR) promoter [34], which we have Pdx1-VP16 is also active, and use of this transgene
previously shown to be liver-specific in Xenopus and to enables specific detection of the endogenous Xlhbox8
become active only after liver differentiation has begun by RT-PCR. In TTR-Pdx1-VP16:Elas-GFP transgenic
[35]. To make it easier to identify the transgenic tadpoles tadpoles, we find that the endogenous Xlhbox8 is acti-
and to monitor the efficiency of the process, GFP was vated in the ectopic pancreas, but not in the normal liver
placed under the control of an elastase promoter (Elas- (data not shown). This result suggests that conversion
GFP) and was included in the same transgene (Figure of liver to pancreas by the transgene occurs by activat-
1A). The elastase element used is a 213-bp fragment of ing the endogenous pancreatic transcription program.
the complete promoter that drives expression in both
endocrine and exocrine cells [36]. Hence, all cell types
in regions of pancreatic tissue are expected to express Structure-Activity Relationship
In order to check that the result was not specific to theGFP. As shown previously in our lab, this elastase pro-
moter drives expression of transgenes in both the dorsal Xenopus form of Pdx1, we tested the activity of the
mouse Pdx1. Like Xlhbox8, when Pdx1 is fused to VP16,and ventral pancreatic buds from stage 35 (2 days) [35].
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Figure 1. Xlhbox8-VP16 Is Able to Cause
Conversion of the Liver into Pancreas
(A) A schematic of the transgene construct
used. The 3-kb liver-specific promoter for
transthyretin (TTR) is used to overexpress
Xlhbox8-VP16 in the liver. The 200-bp pan-
creas-specific elastase promoter driving GFP
expression is used to distinguish transgenic
from nontransgenic animals and to easily
identify the ectopic pancreatic tissue in the
liver.
(B and C) Elastase-GFP transgenic tadpoles
at stage 42 (4 days) and stage 46 (6 days).
(D–I) TTR-Xlhbox8:Elas-GFP transgenic tad-
poles. (D) At stage 40, GFP fluorescence is
only seen in the pancreas. (The fluorescence
visible in the yolk is background). (E–G) Stage-
45–48 tadpoles (5–7 days). (E) Extra Elastase-
GFP fluorescence (EP) can be clearly seen an-
terior and above the endogenous pancreas
(P). The dotted white line separates the two.
(F) Ectopic pancreatic tissue encircles a part
of the liver that has not transdifferentiated
and is located anterior to the endogenous
pancreas. (G) Half of the former liver is ex-
pressing GFP. The dorsal and ventral pan-
creas buds are visible on either side of the
gut tube. (H and I) A specimen at 6 days and
11 days, indicating long-term stability of the
ectopic pancreas. L, liver; P, normal pan-
creas; EP, ectopic pancreas.
it is able to bring about conversion of liver to pancreas, teins [41, 42]. In fact, Pdx:Pbx binding has been shown
to be important for making exocrine cells [43], as wellwhile the unmodified Pdx1 cannot (Figure 3 and data
not shown). To determine what portions of the coding as for the normal proliferation of pancreatic cells [44]
and for transcriptional activity [45, 46]. The interactionregion of Xlhbox8 are necessary, we investigated the
biological activity of various modifications of Xlhbox8 of Pdx1 with Pbx occurs through the pentapeptide motif
FPWMK located upstream of the homeodomain [41, 47].(Figure 3). Two different DNA binding domain (DBD) mu-
tants were constructed: first, the complete homeodo- We eliminated Pbx binding by changing FPWMK to
FPAAA, but this did not reduce the biological activitymain was removed, and, second, a single amino acid
change, which is known to abolish DNA binding, was (Figure 3).
The N-terminal activation domains of Xlhbox8 andproduced within helix three of the homeodomain
(WFQNRR → WFQSRR). When these constructs were Pdx1 have been shown to be essential to their functions
[48]. We wished to determine the importance of thisoverexpressed in the liver, ectopic pancreas was not
produced in either case (Figure 3). We established that endogenous activation domain in the ability of Xlhbox8-
VP16 to convert liver to pancreas, especially since wethese fusion proteins are expressed, as shown by VP16
staining in HepG2 cells (see below). had added on an extra activation domain. To test this,
we made a construct in which the VP16 was placed atXlhbox8 belongs to the ParaHox subfamily, and nu-
merous experiments have shown that the specificity of the N-terminal end and substituted for the first 90 amino
acids. When overexpressed in the liver, this constructhomeodomain proteins is generated by interactions with
other transcription factors, including Pbx and Meis pro- is active and is able to induce ectopic pancreas, but at a
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Figure 2. Endocrine and Exocrine Cells Are Both Present in Ectopic Pancreas
(A–F) Expression of endocrine genes. (A–C) Insulin RNA expression; (D–F) glucagon RNA expression. (A) Wild-type insulin expression. Expression
is only seen in the dorsal pancreas (black arrow) at this stage in several prominent clusters. The liver (L) is located on the opposite side of
the duodenum (red arrowhead). The two dark spots on the stomach are melanocytes and not insulin-stained cells. (B) TTR-Xlhbox8-VP16
transgenic whole gut. Several ectopic clusters of insulin expression are seen in the ectopic pancreatic tissue (EP) opposite the pancreas
(outlined in white). (C) Section of (B) showing the ectopic pancreas (EP, dotted line) opposite the endogenous pancreas (solid line) with two
clusters of insulin-expressing cells. (D) Wild-type glucagon expression. Expression is seen in several spots within the pancreas. (E) TTR-
Xlhbox8-VP16 transgenic gut. Ectopic glucagon expression is found in the position of the liver (EP, outlined in white) opposite the normal
pancreas. Note that glucagon cells are normally found in stomach and intestine, as well as pancreas, but not in the liver [37–39]. (F) Section
of (E) showing glucagon expression within the ectopic pancreas (dotted line).
(G–I) Ectopic expression of exocrine markers in the liver of transgenic tadpoles. (G) Live image of a TTR-Xlhbox8-VP16:Elas-GFP transgenic
tadpole, showing ectopic elastase-GFP fluorescence within the liver (red arrowhead), anterior to the normal pancreas (P). (H) Amylase RNA
expression. Ectopic expression of amylase is seen in the position of the liver (EP) as well as in the normal pancreas (P), in an identical pattern
to the Elas-GFP. (I) Section of (H) showing expression of amylase in a portion of the liver (L), as highlighted by the dotted line. Normal amylase
RNA expression is seen throughout the pancreas (solid black line). L, liver; P, normal pancreas; EP, ectopic pancreas.
somewhat lower frequency than the construct described the liver has undergone conversion, we find TTR expres-
sion in the half that has not been changed to pancreasabove, which contains the endogenous Xlhbox8 activa-
tion domain (Figure 3). Taken together, the results dem- (Figure 4C). These results demonstrate that endogenous
liver markers are quickly downregulated in the ectopiconstrate that the DNA binding domain and the VP16
domain are essential for conversion of liver to pancreas, pancreas.
while the endogenous activation domain and the Pbx
binding region are not necessary.
Pancreatic Tissue Arises from Differentiating
Liver Cells
Because the experiments concern a larval form, the Xe-Liver Gene Expression Is Turned Off
in the Ectopic Pancreas nopus tadpole, in which the tissues are not fully differen-
tiated, we have investigated carefully whether the effectTo confirm that the ectopic pancreatic tissue has lost
expression of liver genes, we examined the transgenic represents a transdifferentiation event or the alteration
of the developmental fate of uncommitted endodermaltadpoles for expression of the endogenous Xenopus
transthyretin (TTR) mRNA [49]. At stage 45 in normal tissue. Previous work has shown that liver differentiation
products begin to be expressed at stage 32, about 2tadpoles, TTR mRNA is present only in the liver (Figure
4A) [50]. When individual TTR-Xlhbox8-VP16 transgenic days of development [50], and that by stage 40/41, 3
days of development, the liver has formed as a separatetadpoles are examined (Figures 4B and 4C), we find
variations in endogenous TTR expression in a precise organ. We have compared the timing of TTR promoter
activation with the temporal expression of two livercomplementary pattern to the ectopic pancreatic tissue
seen with Elas-GFP (see Figure 1). When the whole liver markers, Xhex (a homeobox gene) [51] and AMBP (1-
microglobulin/bikunin precursor) [52]. Both Xhex andis converted to pancreas, no expression of endogenous
TTR is detected (Figure 4B). However, when only half AMBP mRNAs are specifically expressed in a region
Conversion of Liver to Pancreas
109
Figure 3. Domains Necessary for Xlhbox8 to Convert Liver to Pancreas
This is a schematic diagram illustrating the different Xlhbox8 mutants made with their biological activity. Xlhbox8-VP16 is able to convert the
liver to pancreas (68/112 cases), while Xlhbox8 alone is not (0/20 cases). Replacement of the endogenous Xlhbox8 activation domain with
VP16 reduces the ability of Xlhbox8-VP16 to cause conversion of the liver by about 50% (6/18 cases). By mutating the pentapeptide motif
FPWMK to FPAAA, Pbx binding is disrupted. This mutation has little effect on transdifferentiation (11/17 cases). Two DNA binding mutants
were made: the first was a point mutation in helix 3 of the homeodomain changing the amino acid Asparagine to Serine, and the second
removed the entire homeodomain. Neither of these mutants is able to convert the liver to pancreas (both 0/20 cases). The murine Pdx1 gene
was also tested, and similar results were obtained to those with Xlhbox8. Pdx1-VP16 was able to cause conversion of liver to pancreas to a
slightly lesser degree than Xlhbox8-VP16 (7/14 cases). The unmodified Pdx1 cDNA, however, was inactive (0/20 cases).
just posterior to the heart, and their presence identifies Although it is true that the hepatocytes in the 4-day-
old tadpole are not fully mature, and other liver cell typesthe future liver as early as stage 35 (2 days) (Figures
4E–4H). In contrast, the TTR promoter does not become are not yet visible, these results all show that the liver
is already differentiating by the time that expression ofactive until stage 44 (4 days) (Figures 4I and 4J). This
means that, prior to TTR promoter activation, both Xhex the transgene is initiated. We therefore feel that the
effect is appropriately described by the term “transdif-and AMBP have been expressed for 2 days, and the
liver has been separated as a discrete organ for 1 day. ferentiation.”
Note that the expression of endogenous TTR is not quite
the same as that of the TTR promoter we have used. In Xlhbox8-VP16 Causes Conversion of Human Liver
Cells to Pancreasaddition to the pattern shown here, the endogenous
gene also shows an early phase of activation in the In order to determine that the biological activity of
Xlhbox8-VP16 is not confined to Xenopus, or to the larvalwhole endoderm, excluding the liver [50].
When TTR-Xlhbox8-VP16:Elas-GFP transgenic tad- stages of development, we investigated the effects of
transfecting the same construct into the human liverpoles are examined at stage 40/41, before activation of
the TTR promoter, the GFP fluorescence can be seen cell line, HepG2. This cell line shows a large number of
properties of differentiated hepatocytes, including ex-in the normal pancreatic buds, but not in the liver (Figure
1D). Cases fixed at this stage showed the presence of pression of albumin, transferrin, and transthyretin [53,
54], and it does not express specific pancreatic markers.Xhex mRNA throughout the liver as normal and showed
the presence of GFP mRNA only in the pancreas As expected, the elastase promoter is not active in these
cells (data not shown), but it is active in pancreatic cell(Figure 4D).
In addition to this evidence that the liver is already lines such as AR42J [12]; however, the TTR promoter is
expressed in HepG2 cells, but not in AR42J cells (seedifferentiating, it is significant that, in some cases, there
is a complete transformation of liver to pancreas. Al- Figure 5D).
A total of 4–5 days after transfection of HepG2 cellsthough we cannot exclude the participation of some
persisting undifferentiated endodermal cells in this pro- with TTR-Xlhbox8-VP16:Elas-GFP, a number of cells
positive for GFP fluorescence were clearly visible, indi-cess, the fact that the whole organ can be transformed
means that at least some of the ectopic pancreas must cating the activation of the elastase promoter. As men-
tioned above, the element used is active in both exocrinehave arisen from the differentiating hepatocytes.
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Figure 4. Liver Gene Expression in Trans-
genic Gut Preparations
(A–C) Transthyretin (TTR) RNA expression. (A)
In wild-type preparations, expression is only
seen within the liver. (B and C) TTR-Xlhbox8-
VP16 transgenics. (B) In this case, there is
complete conversion of liver to pancreas, and
transthyretin expression has been com-
pletely suppressed. (C) In this case, half the
liver has changed into pancreas, and trans-
thyretin expression is seen only in the other
half. In all examples, nontransgenic guts were
stained simultaneously with transgenic guts,
and the staining reaction was stopped in both
when the nontransgenic expression was
clearly evident.
(D) Liver differentiation begins normally in
TTR-Xlhbox8-VP16 tadpoles. Xhex (blue) and
GFP (magenta, driven by the elastase pro-
moter) expression. GFP RNA is seen only in
the dorsal and ventral pancreas at stage 40;
no GFP expression is detected in the liver.
Xhex expression is normal at this stage and
is present throughout the whole liver.
(E–H) Timing of liver differentiation in normal
nontransgenic tadpoles: from 3 days, the liver
has become a separate organ, with Xhex and
AMBP expressed throughout. (E) Xhex RNA
at stage 40 (3 days). (F) Xhex RNA at stage
45 (5 days). (G) AMBP RNA at stage 40 (3
days). (H) AMBP expression at stage 45 (5
days).
(I and J) The TTR promoter becomes active
in Xenopus tadpoles only after the liver has
differentiated. This shows RNA in situ hybrid-
ization for GFP driven by the TTR promoter.
(I) At stage 40 (3 days), no GFP expression is
detected. (J) GFP expression is first detected
at stage 44 (4 days).
and endocrine cells [36]. Immunostaining for amylase ferrin. HepG2 cells transfected with TTR-Xlhbox8-
VP16:Elas-GFP were double stained for GFP (pancreaticand for insulin showed that a proportion of the GFP-
positive cells expressed one of these differentiation fate) and transferrin (hepatic fate). Transferrin is abun-
dantly expressed in nontransfected cells (Figure 6A).products (Figures 5B, 5C, 5E, and 5F), thus demon-
strating that they are now differentiated pancreatic cells. In cells undergoing conversion to pancreas, however,
transferrin expression is downregulated (Figure 6B).This shows that the activity of the Xlhbox8-VP16 con-
struct is not confined to Xenopus but can also drive These results are in agreement with the Xenopus results
and show that, upon conversion to pancreas, hepato-human liver cells to form both pancreatic exocrine and
endocrine cells. A similar result has also been obtained cyte gene expression is shut off.
In order to quantify the effect, we compared the pro-for the rat FAO hepatoma line (data not shown).
To confirm that hepatocyte gene expression is being portion of green fluorescent cells produced by transfec-
tion of TTR-Xlhbox8-VP16:Elas-GFP with the proportiondownregulated in HepG2 cells during the process, we
have examined the expression of a liver protein, trans- obtained by transfection of CMV-GFP. Assuming that
Conversion of Liver to Pancreas
111
Figure 5. Conversion of Human Liver HepG2 Cells to Pancreatic Endocrine and Exocrine Cells
(A–H) HepG2 cells were transfected with either control plasmid CMV-nGFP or the TTR-Xlhbox8-VP16:Elas-GFP construct and were immuno-
stained for either (A–C) GFP and Insulin (5 days) or (E–G) GFP and Amylase (4 days). All pictures were taken with the confocal microscope;
(D) and (H) have bright field overlay. (A and E) HepG2 cells transfected with CMV-nGFP are only positive for GFP. (B, C, F, and G) HepG2
cells transfected with TTR-Xlhbox8-VP16:Elas-GFP show both (B and C) Insulin- and (F and G) Amylase-positive cells that colocalize with
GFP. A total of 15% (14/94) of the GFP-positive cells were also insulin positive; 12% (11/90) of the GFP-positive cells were also amylase
positive. The scale bars for (A)–(C) and (E)–(G) represent 10 m. (D) HepG2 cells transfected with TTR-nucGFP demonstrating activation of
the TTR promoter. The scale bar represents 20 m. (H) Live image of AR42J-B13 cells transfected with TTR-Xlhbox8-VP16:Elas-GFP showing
that the elastase promoter is active in AR42J cells. The scale bar represents 50 m.
the transfection efficiency is the same for the two con- from liver to pancreas have already commenced differ-
entiation, and we have confirmed here that liver differen-structs, this should give the proportion of cells receiving
TTR-Xlhbox8-VP16:Elas-GFP that are converted from a tiation products are already expressed for about 2 days
prior to the activation of the TTR promoter (Figure 4).hepatic to a pancreatic phenotype (Figures 6C–6E). This
proportion is about 65%, similar to the proportion of We cannot exclude the presence of some residual undif-
ferentiated cells in the liver in addition to the differenti-Xenopus tadpoles in which part or all of the liver is
converted to pancreas (Figure 6C). In Figures 6F and ated cells, but the fact that a complete organ transforma-
tion is possible in some cases argues against pancreatic6G, cells transfected with TTR-Xlhbox8-VP16:Elas-GFP
and coimmunostained for VP16 protein and GFP are tissue arising only from undifferentiated stem cells in
the liver.shown. These results concur in showing that a high
proportion of differentiated liver cells receiving the con- The TTR promoter used is inactive in the pancreas,
and, when it is used to drive Xlhbox8-VP16 in the liver,struct are converted into pancreatic cell types.
it rapidly becomes shut off as the cells are converting
to pancreas. This means that the expression of theDiscussion
Xlhbox8-VP16 protein is only transient. The ectopic pan-
creas, however, persists, showing that, once the ensem-Our results demonstrate that it is possible to bring about
ble of endogenous pancreatic regulatory genes haveconversion of liver to pancreas by overexpression of an
been activated by Xlhbox8-VP16, the transdifferentia-activated form of Pdx1, both in vivo and in vitro. The
tion becomes irreversible. If the procedure were one dayXenopus experiments clearly show the formation of ec-
developed into a therapeutic method, this fact indicatestopic whole pancreas in a normal, intact, vertebrate or-
that only a transient expression of the construct wouldganism. The HepG2 experiments show that the same
be necessary. This would enable a wide variety of geneconstruct can produce a very similar effect in human
delivery methods to be employed, and it means that theliver cells, and the results from these experiments dem-
procedure is more likely to be a safe one, since noonstrate that the result is a general one and not restricted
permanent genetic changes would be required.to Xenopus, or to the larval stage of vertebrate develop-
ment. A recent paper [55] has shown formation of pan-
creatic cells from a type of liver stem cell, hepatic oval An Extra Activation Domain Is Essential
to the Activity of Pdx1cell, following long term culture in a high-glucose
medium. We have not succeeded in obtaining pancreatic transdif-
ferentiation of the liver in either Xenopus or mammalianWe believe that the process is a genuine transdifferen-
tiation. In the Xenopus tadpole, the cells we are changing cells by using unmodified Pdx1, and this accords with
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the experience of other workers. Grapin-Botton et al.
overexpressed Pdx1 in the chick embryo gut by using
electroporation [27]. No ectopic pancreas markers were
activated, although endogenous gut markers were
downregulated. Heller et al. used the Hoxa4 promoter
to drive expression of Pdx1 in the mesoderm of the
stomach and hindgut [28]. Again, no ectopic pancreas
markers were activated, although defects were ob-
served within the Hoxa4 domain. The experiments by
Ferber et al. used an adenovirus to introduce Pdx1 into
the liver [26]. There was some insulin synthesis by a
small proportion of liver cells in vivo, but no evidence
was presented for any actual transdifferentiation of liver
cells to pancreas cells. Furthermore, no insulin was de-
tected in hepatocytes infected with Pdx1 in vitro. As
well as being necessary for early pancreatic develop-
ment, Pdx1 is also a specific transcription factor for
the insulin gene itself [56], and it is possible that the
formation of insulin in the in vivo experiments of Ferber
et al. simply demonstrates a low ectopic activation of
the insulin gene rather than true transdifferentiation.
There are several reasons to explain why our modifica-
tion of Pdx1 is active while the unmodified Pdx1 is not.
First, the necessary transcription partners required for
Pdx1 to bring about normal differentiation of the pan-
creas are absent from the liver. Pdx1 and other homeo-
domain proteins have been shown to require interac-
tions with other proteins, such as Pbx and Meis, for
proper function [42]. Without these protein partners,
overexpression of the unmodified Pdx1 is insufficient to
activate the pancreatic differentiation program, while
VP16 can activate transcription in the absence of protein
partners. Second, regulation of transcription by se-
quence-specific DNA binding proteins requires addi-
tional factors, termed coactivators [57]. The activity of
Pdx1 may therefore require certain coactivators or
adaptors, such as a particular histone acetyltransferase,
that are not expressed in the liver. The addition of VP16
may overcome this lack of coactivators, as VP16 is
known to interact directly with transcriptional adaptors
[58]. Third, the chromatin surrounding the downstream
targets of Pdx1 may be in a repressed state. Epigenetic
Figure 6. Estimate of the Proportion of Cells Transfected with TTR- regulation of transcription during development and dif-
Xlhbox8-VP16:Elas-GFP that Are Converted to Pancreas
ferentiation maintains the cellular phenotype over many
(A and B) TTR-Xlhbox8-VP16:Elas-GFP-transfected HepG2 cells im-
generations, and this is thought to be regulated partlymunostained for either (A) Transferrin or (B) Transferrin and GFP.
at the level of chromatin [59]. For example, the PolycombThe cells undergoing transdifferentiation to pancreas have down-
group of proteins is thought to function to maintain aregulated transferrin expression (arrow).
(C–G) (C–F) Estimate of the proportion of cells transfected with repressive chromatin structure [60]. This regulation is
TTR-Xlhbox8-VP16:Elas-GFP that are transdifferentiated. (C) The thought to prevent inappropriate activation of one pro-
histogram shows aggregated counts of GFP-positive cells in five gram in an ectopic location; such activation can be
random fields; the bars indicate the standard deviations. Assuming harmful, as seen in neoplastic transformations. VP16 is
a similar transfection frequency, this shows that the proportion of
known to interact with chromatin remodeling com-transdifferentiation of cells transfected with Xlhbox8-VP16 is about
plexes, resulting in increased transcription and histone65%. (D) and (E) show fields of cells stained with DAPI and trans-
fected with either (D) CMV-nGFP or (E) TTR-Xlhbox8-VP16:Elas- acetylation [61, 62]. Fourth, other proteins that act as
GFP. (F and G) Immunostain for VP16 protein (red) and GFP (green) repressors may bind to Xlhbox8 in the liver and prevent
in cells transfected with either (F) TTR-Xlhbox8-VP16:Elas-GFP or it from activating the pancreatic transcription cascade
(G) TTR-Xlhbox8-VP16:Elas-GFP(N → S). The presence of VP16 on its own. Since the liver and pancreas arise from adja-
staining in (G) demonstrates that the fusion protein is produced. A
cent positions in the early embryo, the presence of asimilar result was also obtained with TTR-Xlhbox8-VP16:Elas-
repressor in the liver may be important to restrict theGFP(HD) and TTR-Xlhbox8-VP16:Elas-GFP(Pbx). (A), (B), (F), and
development of the pancreas and prevent ectopic acti-(G) are all confocal images.
vation of the pancreatic differentiation program in the
liver. Fifth, Xlhbox8 may be targeted for destruction by
ubiquitination in liver cells, thus again preventing ec-
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The FPWMK → FPAAA PBX binding mutant was made by PCRtopic activation. This has been shown to occur with
isolating separate 5 and 3 ends of Xlhbox8-VP16 and then ligatingGCN4, E2F-1, and even VP16 [63–67]. All of the above
them together. The 5 end was isolated by PCR with the SP6 primerreasons lead to the conclusion that tight control of tran-
plus the WMK → AAA reverse primer, 5-TTTGGTGGATGCGGCCG
scription factors within their allotted domains is essen- CTGGGAAAGG-3. The 3 end was isolated by PCR with the WMK→
tial for correct development and differentiation to occur. AAA forward primer, 5-CCTTTCCCAGCGGCCGCATCCACCAAA-3,
plus an internal VP16 primer. The 5 PCR product was cut with ClaIBy fusing VP16 to Xlhbox8, we have been able to bypass
and NotI, and the 3 PCR product was cut with NotI-SacI and in-these various checkpoints and induce the ectopic acti-
serted into the ClaI-SacI site of pBS KS. This WMK → AAA mutantvation of the pancreatic differentiation program in the
was then cut with ClaI and cloned into the ClaI site of TTR-Xlhbox8-liver.
VP16:Elas-GFP. The DNA binding mutants of Xlhbox8 were made
as follows. The N → S amino acid change was made by a similar
procedure used for the WMK→ AAA mutant. The 5 end of Xlhbox8Conclusions
was PCR isolated with the SP6 primer plus the N→ S reverse primer,Our current results demonstrate that a transient overex-
5-CTTCATTCTTCTAGACTGGAACCA-3, containing an internalpression of Xlhbox8-VP16 is sufficient to convert differ-
XbaI site. The 3 end was PCR isolated with the N → S forwardentiating or differentiated liver cells into pancreatic cells,
primer, 5-TGGTTCCAGTCTAGAAGAATGAAG-3, containing an in-
producing both endocrine and exocrine cell types. The ternal XbaI site plus an internal VP16 primer. Both PCR products
ability to convert liver to pancreas may provide a useful were cut with ClaI and XbaI and inserted into the ClaI site of TTR-
Xlhbox8-VP16:Elas-GFP. The homeobox deletion was made as fol-therapy for diabetes. These results, in combination with
lows. The 5 end of Xlhbox8 was PCR isolated with the X8-our previous results [12], suggest that it may be possible
160XbaRev primer, 5-CTCTAGTTCTAGAAGCTGGGCT-3, whichto bring about the transdifferentiation of other tissue
contains an internal XbaI site. The 3 end was PCR isolated as abovetypes by using specific promoters and transcription fac-
with the X8-216XbaFor primer, 5-GGCAGTGATCTAGAACAAGA
tors. Our understanding of the normal hierarchy of cellu- CTC-3, which contains an internal XbaI site. Both 5 and 3 ends
lar commitment [68] indicates that it should be easiest were cut with ClaI and XbaI and inserted into the ClaI site of TTR-
Xlhbox8-VP16:Elas-GFP.to interconvert tissues that are closely related in devel-
opment, such as liver and pancreas, since their forma-
Whole-Mount In Situ Hybridizationtion should depend on differential expression of the
Whole-mount in situ hybridization was performed according to [69]smallest number of transcription factors. In principle,
by using digoxygenin- and fluorescein-labeled probes. All series
the most useful factors should be those that normally included positive controls to ensure consistency in staining intensity
act at the earliest developmental stage to distinguish between transgenic and nontransgenic whole guts. Xenopus amy-
two tissue types. But more complex protocols involving lase was cloned by degenerate PCR into pCR Script as described
by Horb and Slack [37]. For antisense RNA, it was linearized withmodified transcription factors or combinations of fac-
EcoRV and transcribed with T3. Xenopus insulin was cloned by PCRtors could bring about transdifferentiation between
based on published sequence (ntds 3–752) into pCR Script and wasmore distantly related tissues as well. The prospect of
linearized with EcoRI and transcribed with T3. Xenopus glucagon
tissue replacement by transdifferentiation is a new area was cloned by PCR based on published sequence (ntds 1–1151)
of therapy and opens up wide ranging possibilities for into pCR Script and was linearized with NotI and transcribed with T7.
regenerative medicine. Xenopus transthyretin (TTR) was cloned by PCR based on published
sequence (ntds 10–500) into pCR Script and was linearized with
EcoRI and transcribed with T3. Xenopus hex (Xhex) (kind gift of P.Experimental Procedures
Krieg) was linearized with NotI and transcribed with T7. Xenopus
1-microglobulin/bikunin (AMBP) (kind gift of A. Kawahara) wasTransgenesis
linearized with SacI and transcribed with T7. For double-in situ hy-Transgenic Xenopus laevis tadpoles were produced according to
bridization, fluorescein-labeled probes were detected first with 175Kroll & Amaya [33] with slight modifications as described in [35],
g/ml magenta phosphate (5-bromo-6-chloro-3-indolyl phosphate,except for the following two changes. First, the high-speed cyto-
Molecular Probes Europe) and heat inactivated, and then the digoxy-plasmic egg extract was heat treated for 8 min at 80C and was
genin-labeled probes were detected with 175 g/ml BCIP.recentrifuged at 70,000 rpm for 10 min. A total of 10 l cytoplasmic
extract was then used for each reaction. Second, no restriction
enzymes were included in the incubation of sperm and transgene Transfection of Mammalian Cells
DNA. A total of 5–10 g transgene DNA was linearized with either HepG2 cells were obtained from the ECACC (CAMR) and were main-
SacII or NotI, extracted with phenol/chloroform, and ethanol precipi- tained in Dulbecco’s modified Eagle’s medium containing penicillin,
tated. The DNA was resuspended to a final concentration of 0.5 g/ streptomycin (Sigma), and 10% fetal bovine serum (Invitrogen).
l; 0.5 g DNA was used to make transgenics. To visualize GFP Transient transfectants of HepG2s were generated with TTR-
fluorescence, tadpoles were anaesthetized in a 1:2000 dilution of Xlhbox8-VP16:Elas-GFP or with CMV-GFP (control for transfection
MS-222 (3-aminobenzoic acid ethyl ester, Sigma) and were visual- efficiency). Cells were seeded in 35-mm dishes and grown at 37C
ized by using a Leica Fluo III fluorescent-dissecting microscope. in 5% CO2 overnight and were then transfected with 2 g DNA by
using GeneJuice transfection reagent (Novagen) and incubated for
an additional 5 days. For counting, they were fixed in 4% PFA andTransgene Constructs
immunostained for GFP. Using the 20 objective, five fields wereTTR-Xlhbox8-VP16:Elas-GFP was constructed as follows. Full-
picked randomly from each dish and were photographed with alength Xlhbox8 was PCR isolated from Xlhbox8-CS2 (kind gift of C.
digital (Spot) camera under DAPI and GFP fluorescence. The cellWright) by using the SP6 primer and a 3 primer with a ClaI site, 5-
number in each field was 300. The error bars represent standardTTTATCGATTTCTGCCTGCC-3. It was cut with ClaI and subcloned
deviations. For assessing pancreatic differentiation, they were im-into the ClaI site of VP16-N (kind gift of D. Kessler). The 3-kb TTR
munostained for both GFP and either insulin or amylase.promoter (kind gift of R. Costa) was cut with BamHI and filled in
with Klenow and cloned upstream of Xlhbox8-VP16 in the HindIII
(blunt) site. Lastly, the Elastase-GFP (kind gift of G. Swift) was ex- Immunostaining
Cells were cultured on glass coverslips, rinsed with PBS, fixed withcised with NotI and cloned into the NotI site of TTR-Xlhbox8-VP16.
The resultant plasmid, pCS2-TTR-Xlhbox8-VP16:Elas-GFP, is 10.5 4% paraformaldehyde in PBS for 30 min, permeabilized with 0.1%
(v/v) Triton X-100 in PBS for 30 min, blocked in 2% Roche blockingkb. For TTR-GFP and Elas-GFP, the transgene DNA was digested
as described in [35]. buffer in PBS, and then incubated sequentially with primary and
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secondary antibodies. Antibodies were used at the following con- G. (1990). Exocrine pancreatic tissue in human liver: a metaplas-
tic process? Am. J. Surg. Pathol. 14, 590–595.centrations: rabbit anti-amylase, Sigma (1/300); guinea pig anti-insu-
lin, Sigma (1/250); rabbit anti-VP16, Clontech (1/100); mouse mono- 16. Wells, J.M., and Melton, D.A. (1999). Vertebrate endoderm de-
velopment. Annu. Rev. Cell Dev. Biol. 15, 393–410.clonal anti-GFP, Clontech (1:200); TRITC goat anti-guinea pig IgG,
Sigma (1/200); FITC horse anti-mouse IgG, Vector (1/150); TRITC 17. Deutsch, G., Jung, J., Zheng, M., Lora, J., and Zaret, K.S. (2001).
A bipotential precursor population for pancreas and liver withinswine anti-rabbit IgG, Dako (1/150). DAPI was dissolved in PBS
at 500 g/ml and was used at a 1:1000 dilution. Coverslips were the embryonic endoderm. Development 128, 871–881.
18. Jung, J., Zheng, M., Goldfarb, M., and Zaret, K.S. (1999). Initia-incubated with DAPI (500 ng/ml) for 5 min at room temperature.
After the immunostaining steps were completed, the coverslips were tion of mammalian liver development from endoderm by fibro-
blast growth factors. Science 284, 1998–2003.mounted on slides in gelvatol medium (20% polyvinyl alcohol in 10
mM TrisCl [pH 8.6]). 19. Kim, S.K., and Hebrok, M. (2001). Intercellular signals regulating
pancreas development and function. Genes Dev. 15, 111–127.
20. Dohrmann, C., Gruss, P., and Lemaire, L. (2000). Pax genes andAcknowledgments
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